Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HY02 Ointment in Inflamed Meibomian Gland Dysfunction
NCT03888378Phase 2Completed
- Sponsor
- Hovione
- Start
- Apr 2019
- Primary completion
- Sep 2020
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of zilxi in meibomian gland dysfunction (MGD) (3 arms), sponsored by Hovione. Primary endpoints: Change from baseline in Vascular Engorgement at 12 weeks and Change from baseline in Eye Discomfort Visual Analogue Score at 12 weeks. Started Apr 2019; status: completed.
02
Drugs
zilxi
03
Conditions
meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on NCT03888378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03888378.